Cell division cycle 37 (Cdc37) is an important partner for heat shock protein 90 (HSP90), assisting in molecular chaperone activities, particularly with regard to the regulation of protein kinases. Given its influence on cell growth pathways, Cdc37 has been discussed as a potential intermediate in carcinogenesis. However, to date, the potential functional roles and molecular mechanisms by which Cdc37 regulates cell survival in colorectal carcinoma (CRC) remain unclear. Here, we investigated the expression of Cdc37 and its clinical significance in CRC, and systematically explored the role and the underlying mechanism of Cdc37 in CRC cell survival both in vitro and in vivo. Our results showed that Cdc37 was remarkably up-regulated in CRC, which facilitated cell survival mainly by promoting cell proliferation, G1-S transition, and inhibiting cell apoptosis. Our data further indicated that Cdc37 increased the stability of cyclin-dependent kinase 4 (CDK4) to activate the retinoblastoma 1 (RB1) signaling pathway, followed by increased expression of Bcl-2 and Bcl-xL, which ultimately promoted cell survival in CRC. Moreover, knockdown of CDK4 reversed the Cdc37-mediated effect in promoting the progression of CRC. Our findings showed that Cdc37 played a critical role in promoting CRC cell survival by increasing CDK4 stability to activate the RB1 signaling pathway.
Cdc37, as a protein kinase-specific adaptor co-chaperone of HSP90, functions as a scaffold protein to recruit protein kinase client to HSP90, followed by protecting the protein kinase client from degradation, resulting in increased protein stability and kinase activity. 3 Through genetic screens in Drosophila, Cdc37, also named as p50, was identified to be an essential component of the MAPK signaling pathway. 5 proliferation was inhibited, cell cycle was arrested at the G1 phase, and apoptosis was enhanced after Cdc37 knockdown in HCC cells.
Meanwhile, Cyclin D1, CDK4, and p-RB were down-regulated upon Cdc37 knockdown, resulting in the arrest of cell cycle progression at the G1 phase 7 . Guo et al 8 also reported that the expression levels of Cdc37 were up-regulated in HCC cell lines. Overexpression of Cdc37 in HCC cells increased cell proliferation, invasion activity, and protein levels of Akt, which suggested that Cdc37 promoted cell proliferation and invasion through stabilizing and activating Akt.
Although the functional roles of Cdc37 have been elaborately explored in HCC, little useful information is known in other malignancies. Stepanova reported that Cdc37 displayed increased expression in human prostatic tumors, neoplasias and certain pre-malignant lesions, suggesting an important function for Cdc37 in prostatic transformation. 9 Cdc37 was identified as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors through genome-wide functional screening. 10 Smith et al 11 showed
that knockdown of Cdc37 in human colon cancer cells attenuated association of kinase clients with HSP90 and decreased levels of the clients ERBB2, CRAF, CDK4 and CDK6, as well as phosphorylated Akt. Moreover, combining Cdc37 knockdown with the HSP90 inhibitor 17-AAG induced more extensive depletion of kinase clients and potentiated cell cycle arrest and apoptosis. However, to date, the potential functional roles of Cdc37 in CRC are not clear. In the present study, we systematically investigated the expression of Cdc37 and its functional roles in CRC cell survival both in vitro and in vivo.
More importantly, the underlying molecular mechanisms were thoroughly explored.
| MATERIALS AND METHODS

| Antibodies and reagents
Primary antibodies used in this study are provided in Table S1 .
Detailed information of the reagents is described in Doc S1. 
| qRT-PCR, western blot and IHC
RNA extraction, cDNA synthesis, and qRT-PCR reactions were carried out as described in Doc S1. Primer sequences were synthesized by Sangon Biotech (Shanghai, China) and are provided in Table S2 .
Western blot and immunohistochemistry (IHC) analysis was carried out as described in Doc S1. Table S2 . Two days later, the transfected Lovo cells were cultured in medium containing 1000 lg/mL G418. After 14 days, monoclonal cells were selected and cultured in the medium containing 500 lg/mL G418.
The new constructed cell lines generated from the corresponding monoclonal cells were named Lovo-shCdc37 and Lovo-Cdc37, respectively. 
| TUNEL assay
For analysis of apoptosis in xenograft tissues, TUNEL assay (Roche Applied Science, Rotkreuz, Switzerland) was carried out according to the manufacturer's protocol. Briefly, sections were incubated with Proteinase K (Sigma, Munich, Germany) at 37°C for 30 minutes, followed by incubating with TUNEL reaction buffer at 37°C for 1 hour protected from light. Then, cell nucleus was stained by DAPI (Beyotime). Images of TUNEL/DAPI-stained sections were taken by a fluorescence microscope (DM5000B; Leica, Heerbrugg, Switzerland).
| Protein stability assay
For protein stability experiments, cells were seeded in 6-well plates.
Forty-eight hours later, cycloheximide (50 lg/mL) was added to the cells, and this time was marked as 0 hours. Cell samples were collected at 0 hours, 2 hours, 4 hours and 6 hours after cycloheximide treatment, respectively. Protein levels were analyzed by western blot. 3 | RESULTS
| Co-immunoprecipitation
| Cdc37 is up-regulated in CRC tissues
In order to explore the functional roles of Cdc37 in CRC, both mRNA and protein expression of Cdc37 was detected by qRT-PCR and western blot in 20 pairs of CRC tissues. Our results showed that both mRNA and protein expression of Cdc37 was up-regulated in CRC tissues when compared with paired non-tumor tissues (P = .005, P = .0008, respectively) ( Figure 1A-C) .
Similarly, IHC staining results also showed that Cdc37 protein expression was significantly increased in CRC tissues compared with paired non-tumor tissues (P < .001) ( Figure 1D ). Furthermore, we analyzed the relationship between Cdc37 expression level and pathological characteristics of CRC patients (Table S3) , and found that Cdc37 expression level in female patients was significantly higher than that in male patients (P = .0450).
Moreover, Cdc37 expression level was gradually increased with the pathological development of CRC, but the difference among them was not statistically significant (P = .1707). Altogether, these results indicate that Cdc37 is up-regulated in CRC, which promotes the development of CRC.
3.2 | Cdc37 promotes CRC cell proliferation and
G1-S phase transition
Next, we investigated the role of Cdc37 in cell growth. As shown in Figure S1 , expression of Cdc37 was significantly increased in Lovo cells when compared with normal colon cells. MTS assays showed that growth rate of CRC cells was significantly decreased after Cdc37 Thus, 17-AAG was used to disrupt the HSP90-Cdc37-client complex, and our results showed that cell growth rate and proliferation activity of CRC cells were significantly reduced after 17-AAG treatment (Figure 2D) . Our results also showed that Cdc37 knockdown promoted cancer cells to accumulate in the G1 phase, whereas overexpression of Cdc37 facilitated cancer cells to enter into S phase ( Figure 2E ). Similarly, 17-AAG also arrested the cells in G1 phase ( Figure 2F ). Taken together, our results suggest that up-regulated Cdc37 facilitates CRC cell growth through promoting G1-S transition.
| Cdc37 inhibits CRC cell apoptosis in vitro
Next, we investigated the functional role of Cdc37 in CRC cell apoptosis. Flow cytometry showed that the apoptosis rate of Lovo cells was significantly increased after Cdc37 knockdown ( Figure 3A) , whereas cell apoptosis induced by 5-FU was significantly decreased after over-expression of Cdc37 in colorectal carcinoma cells ( Figure 3C ). In addition, our results showed that expression of the cleaved form of caspase 3 protein was significantly increased after Cdc37 knockdown ( Figure 3B ), whereas overexpression of Cdc37 protected CRC cells from 5-FU-induced cell apoptosis ( Figure 3D) .
Similarly, the cell apoptotic rate and expression of the cleaved form of caspase 3 were significantly increased after 17-AAG treatment ( Figure 3E,F) . Together, these results indicate that Cdc37 promotes the progression of CRC through inhibiting cell apoptosis.
| Cdc37 facilitates CRC growth in vivo
Our previous data showed that up-regulated Cdc37 promoted cell survival in vitro, but the functional role of Cdc37 in vivo remains unclear.
Stable cell models with knockdown or overexpression of Cdc37 were established, respectively ( Figure S2 ). Here, our data showed that the growth capacity of xenograft tumors developed from Lovo-shCdc37 cells was significantly decreased than that of xenograft tumors developed from control cells, whereas the growth capacity of xenograft tumors developed from Lovo-Cdc37 was significantly increased compared with the control group ( Figure 4A,B) . We further investigated the effect of Cdc37 on cell apoptosis and proliferation activity in vivo using TUNEL staining assay and immunohistochemical staining of Ki67. Our data showed that overexpression of Cdc37 promoted the proliferation activity, and protected CRC from 5-FU-induced apoptosis Figure 5A ). Furthermore, our results showed that Cdc37 had no effect on the protein expression of Cyclin D1, CDK6, and RB1 in CRC. Similarly, the protein level of CDK4 and the phosphorylation of RB1were significantly decreased after 17-AAG treatment ( Figure 5A ). Our data further showed that overexpression of Cdc37 increased the lifespan of CDK4 ( Figure 5B ). In addition, coimmunoprecipitation (co-IP) results showed that Cdc37 protein specifically interacted with CDK4 in colorectal carcinoma cells ( Figure 5C ).
In order to further confirm whether Cdc37-induced phosphorylation of RB1 was conveyed by CDK4, expression of CDK4 was silenced by siRNA in the present study. Our data showed that CDK4 knockdown restrained the promoting growth effect of Cdc37 in CRC cells ( Figure S3 , Figure 5D ). Moreover, our data showed that CDK4 knockdown inhibited the role of Cdc37 in promoting G1-S transition in CRC ( Figure 5E ). CDK4 knockdown significantly reduced the effect of Cdc37-induced phosphorylation of RB1 ( Figure 5F ). Altogether, our results indicate that Cdc37 increases the stability of CDK4 to activate RB1, which ultimately promotes G1-S transition.
| Cdc37 inhibits cell apoptosis by inducing the expression of Bcl-2 and Bcl-xL
Our data showed that overexpression of Cdc37 significantly increased the expression of Bcl-2 and Bcl-xL, but had no effect on the expression of Mcl-1, XIAP and survivin ( Figure 6A,B) . Furthermore, CDK4 knockdown dramatically reversed the anti-apoptotic effect of Cdc37 in CRC cells ( Figures 6C, Figure S4 ). Moreover, CDK4 knockdown remarkably inhibited the effect of Cdc37-induced expression of Bcl-2 and Bcl-xL ( Figure 6D,E) . Altogether, our data strongly indicated that Cdc37 inhibits cell apoptosis by increasing the expression of Bcl-2 and Bcl-xL in CRC.
| Correlational analysis of Cdc37 and CDK4 in CRC tissues
We then investigated the protein expression of Cdc37 and CDK4 in 120 pairs of tumor and peri-tumor colorectal tissues through IHC Figure 7A,B) . Collectively, our data showed that Cdc37 promotes proliferation and inhibits apoptosis in CRC cells through activating CDK4.
| DISCUSSION
Colorectal carcinoma is a common malignancy, and its morbidity rate ranks second for digestive system tumors. 1 As CRC is not easy to diagnose early, it has mostly reached through the serosa and lymph node metastasis has occurred, making it difficult to treat. 2 So far, many oncogenes (survivin, C-myc, Bcl-2 etc.) and anti-oncogenes (p53, DCC, nm23, APC, PTEN) have been identified to be related to the development and progression of CRC. 2 However, many oncogenes still have not been identified, and the functional role of these genes has also not been clarified. Therefore, it is meaningful to con- In budding yeast, Cdc37 is necessary for cells to complete division. 17 Protein kinase Cdc28 and Cak1 became unstable after Cdc37 mutation, and they could not be combined with cell cycle protein to form the cell cycle complex, which ultimately inhibited cell growth and division. 18 In addition, Cdc37 has been shown to be required for the activity and stability of protein kinases that regulate different stages of cell cycle progression. 19 Lange et al 20 showed that the loss of function of Cdc37 in Drosophila triggered defects in mitosis, and provided evidence that Aurora B interacted with and required the Cdc37/Hsp90 complex for its stability, which substantiated the functional role of Cdc37 as an upstream regulatory element of cell cycle kinases. In the present study, our results were consistent with previous findings that Cdc37 promoted G1-S transition in other cell types, 7 and our results also showed that Cdc37 increased the stability of CDK4. CRC cells were arrested in G1 phase and protein expression of CDK4 was decreased after knockdown of Cdc37 or 17-AAG treatment, whereas overexpression of Cdc37 facilitated CRC cells to enter into S stage and increased the protein expression level of CDK4. However, Cdc37 almost had no effect on the expression of Cyclin D1. Taken together, our results suggest that Cdc37 increases the stability of CDK4, resulting in promoting the CRC G1-S transition in CRC.
The activated kinase complex formed by Cyclin D and CDK4 or CDK6 could phosphorylate RB to p-RB protein, release transcription factor E2F, and then activate the expression of related genes, and ultimately promote the cell G1-S phase transition. 21, 22 Herrera-Abreu et al 23 reported that phosphorylation of RB was abolished and that activation of S-phase transcriptional programs was inhibited after reducing the levels of cyclin D1 and other G1-S cyclins. In the present study, our results showed that Cdc37 knockdown inhibited the phosphorylation of RB1, and vice versa, which strongly suggested that RB1 was the downstream regulated molecule of Cdc37 in CRC.
Moreover, phosphorylation of RB1 was abolished after CDK4 knockdown in CRC. Taken together, our results indicate that Cdc37 facilitates the phosphorylating of RB1 through increasing CDK4 stability, which is consistent with the previous reports. 24, 25 In conclusion, our study showed that the Cdc37 gene was up-regulated in human colorectal adenocarcinoma. Furthermore, knockdown of Cdc37 effectively reduced cell proliferation activity, enhanced apoptosis, and inhibited G1-S transition in CRC cells, and vice versa.
For the mechanism, Cdc37 increased CDK4 stability to promote the phosphorylation of RB1, which finally promoted the progression of CRC. In conclusion, up-regulated cdc37 promoted the development of colorectal cancer, and regulation of the Cdc37/CDK4/pRB1 axis might be a potential novel target in CRC treatment.
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